Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Empathbio Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, which suggests a slight concentration of work compared to the total number of actions. The portfolio also spans 4 distinct art units, indicating that the company's biological or pharmaceutical innovations are being reviewed across multiple specialized divisions.
MOU, LIYUAN is the busiest examiner for Empathbio Inc., currently managing 2 pending office actions. This accounts for a significant portion of the 5 total pending office actions, making this examiner's specific tendencies a primary focus for the company's prosecution strategy. The remaining actions are spread across other distinct examiners, requiring the legal team to manage several different examiner relationships simultaneously.
The involvement of 4 distinct art units for the pending office actions highlights a diverse technical footprint within the Biotechnology & Pharmaceuticals sector. Because MOU, LIYUAN handles 2 actions while the other examiners handle the rest, the prosecution effort is relatively decentralized. Practitioners must prepare for the specific requirements of the various art units to successfully navigate the active docket.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 2 | 43.8% | +59.9% |
| JEAN-LOUIS, SAMIRA JM | 1 | 60.9% | +45.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18934442 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERS | JEAN-LOUIS, SAMIRA JM | — |
| 18744218 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19431012 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | MOU, LIYUAN | — |
| 18934442 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERS | JEAN-LOUIS, SAMIRA JM | — |
| 18737447 | SUBSTITUTED BENZOFURAN PROPYL AMINE MODULATORS OF MONOAMINERGIC TRANSPORTERS | FETTEROLF, BRANDON J | — |
| 18401401 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1642 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19431012 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | MOU, LIYUAN | 1628 | §103§112DP | Final Rejection | — | Pending | Dec 23, 2025 |
| 18934442 | CARBAMOTHIOATE, AND CARBAMODITHIOATE DERIVATIVES OF MDMA, MDA OR ITS OPTICALLY ACTIVE (R)- OR (S)-MDMA AND MDA ISOMERS | JEAN-LOUIS, SAMIRA JM | 1642 | §102§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18744218 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §102§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18737447 | SUBSTITUTED BENZOFURAN PROPYL AMINE MODULATORS OF MONOAMINERGIC TRANSPORTERS | FETTEROLF, BRANDON J | 1626 | §102 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18401401 | SALT FORMS OF R-MDMA AND METHODS USING THE SAME | MOU, LIYUAN | 1628 | §102§103§112DP | Non-Final OA | — | Pending | Dec 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmpathbio Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Liyuan Mou has the most, with 2 of Empathbio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
